Seoochre

Billions of dollars are invested every year into the discovery and development of new medicines, but it usually takes 10-15 years for a drug or vaccine to evolve from inception to release. Manufacturers invest a tremendous amount of capital long before seeing any return, which means pharmaceutical companies must allocate a high per centage of the budget to R&D. The fail rate for clinical trials is 92 per cent, and drug companies spend an average of US$2.6 billion developing a single drug.

When a pharmaceutical company invests in Research & Development (R&D), it screens 5,000-10,000 chemica

Biopharma’s efforts to digitally transform operations are proving more important than ever to drive improvements in process efficiency and deliver essential treatments to patients. However, the industry’s attempts are returning mixed results and the digital transformations of many enterprises remain in early-phase development. As with any business initiative, a lack of clear goals and strategies keeps some biopharma programs from being successful. As a result, these shortfalls may be further preventing many companies from moving toward the more data-driven future the industry needs to deliver

To bring this into reality, pharmaceutical PV organisations need to move into a “digitalised future” where technology plays a key role in PV processes. This includes automating and streamlining the information streams to reduce complexity, from case processing to reporting. Once automated, companies need to begin to look to artificial intelligence to add further value from their data.

By applying artificial intelligence (AI) and data science approaches, organisations can turn the overabundance of data from being a challenge to solve, into an opportunity. A well-designed, automated, AI-powe

Soft gels, also known as soft capsules or soft caps, are a highly popular pharmaceutical and nutraceutical dosage form, with around 2,500 units consumed every second globally. A forecast by HJR Research predicts a CAGR of 5.5 per cent over the next decade, with the global market value expected to reach $756 billion by 2025. During the same period, the Asia-Pacific region is projected to be the fastest-growing market at a CAGR of 6 per cent, in terms of value. Driven by the increasing popularity of nutraceuticals, where clean label and comfort in swallowing are key factors in customer buying d

There's a need consolidate natural information with computational strategies for extricating important and fitting qualities from the thousands of qualities measured. Artificial Intelligence (AI) has been connected within the sedate disclosure field for decades. Today, conventional machinelearning modelling has advanced into an assortment of unused strategies, such as combi-QSAR and crossover QSAR, and remains a prevalent approach to consider different drug-related themes. There are different drugs on the showcase and/or in clinical trials that have been outlined by computational strategies.

Controlling the industrial crystallisation process poses a significant obstacle in the production of drugs and numerous other products. Digitisation of the crystallisation process now allows for radical change by increasing process automation to control overall crystallisation. The main pillars of Pharma 4.0 are process automation, improved control strategies, data visualisation, cloud edge storage, chemometrics, and mathematical modelling technologies. SmartCrys is a revolutionary integrated process control system that harnesses the mainstays of Pharma 4.0 with the combination of PAT tools i

Clinical research technology platforms have also emerged, providing participant-facing apps and websites where you can build in or interface with some or all the previously mentioned solutions, as well as expanding to other research-related activities such as virtual training, electronic informed consent form (eICF), participant recruitment, engagement, visit reminders and concierges, etc. Implementing these platforms, the individual participant is given an even more active role in their own research journey, as they are responsible to enter their own subjective data directly into the designa

Artificial Intelligence (AI) and machine learning-based technologies have the potential to transform healthcare because they offer new and important insights derived from the vast amount of data generated during the delivery of healthcare every day. The capacity of AI to learn from real-world feedback and improve its performance makes this technology uniquely suited as Software as a Medical Device (SaMD) and is responsible for it being a rapidly expanding area of research and development. Clinical pharmacy practice may undergo major change due to the implementation of this technology. The cha

The drug business has various strange qualities that make it very different from individuals' thought process of as industry. Its additionally an industry packed with logical inconsistencies; for instance, notwithstanding the undisputed reality that for more than a century the business has made a major contribution to human prosperity and the decrease of chronic sickness and suffering, it is still routinely recognized bygeneral society in assessment reviews as one of the most un-confided in ventures, frequently being contrasted horribly with the atomic business. It is without a doubt perhaps

More than one billion people are impacted by chronic and acute lung diseases globally Infact, non-communicable diseases, such as chronic respiratory diseases are among the biggest reasons for fatality (WHO). Despite the growing health and wellness centricity across countries, respiratory conditions have not received the attention they need. If at all they do then it’s more for infectious conditions like Tuberculosis. But when wellness is looked at holistically, healthy lungs and lung health is paramount for overall health and wellbeing. According to WHO, respiratory illnesses lead to over 10p

Gene therapy, in general, encompasses a wide range of treatments that all use genetic material to modify cells to aid in healing. To understand the long-term benefits, it is necessary to be aware of the obstacles to therapeutic intervention and to have a developed approach to overcome them. In addition to, for example, failures in targeting metastatic cells, obstacles also include ethical issues, since approaches in gene therapy result in integration into the individual’s genome and thus the possibility of transmitting genetic changes to the patient’s offspring. As with any new type of therap

With leading pharma companies such as Novartis rebranding themselves as a ‘Medicine and Data Sciences’ companies (Narasimhan, V, 2018), it is time to sit up and think. Vas Narasimhan, the CEO of Novartis, believed that digital technology could save up to 10 to 25 per cent of the cost of clinical trials (Neville and Atkins, 2017). There are currently 294,244 research studies ongoing in 50 states and in 207 countries (clinical.trials. gov, as of 12th Jan, 2019). A very small percentage of these are virtual clinical trials. While hybrid clinical trials (using at least some components of digital

Cancer drug resistance is complex phenomenon and can be categorised as intrinsic or acquired resistance. In few cases, cancer cells survive even at the clinically relevant doses of established standard chemotherapy which is called as intrinsic resistance whereas at some instances after attaining promising result at initial phases, therapy suddenly turns out to be non-responsive and leads to recurrence of tumour growth. This acquired drug resistance often called as Multi Drug Resistance (MDR) when cancerous cells develop resistance and cross resistance to functionally or even structurally unre

Biologics are basically the products which are developed and produced from living organisms like human, plant or animal cells and, of course, microorganisms (bacteria, yeast, etc.). Having no definite structure, biologics are large and complex molecules which undergo sophisticated procedures while being developed and manufactured. Monoclonal antibodies, hormones, enzymes, insulin, etc. can be referred to as biologics.

Generics are simple molecules and exact copies of approved brand drugs. Contrary to biologics, generics are easier to synthesize, purify and manufacture. Drugs such as phenyt

However, these efforts are haunted by a shortage of resources, restrictions on importing API, social distancing at facilities, disturbed supply chains, and tremendous pressure to quickly manufacture and distribute products. Despite these arduous circumstances, it remains critical for pharma companies to maintain quality and compliance and follow regulatory guidelines. Doing so requires pertinent measures to ensure adherence to Current Good Manufacturing Practice (CGMP) guidelines, and data integrity to meet the requirements of regulators including the U.S. Food and Drug Administration (FDA),

Artificial Intelligence (AI) and machine learning-based technologies have the potential to transform healthcare because they offer new and important insights derived from the vast amount of data generated during the delivery of healthcare every day. The capacity of AI to learn from real-world feedback and improve its performance makes this technology uniquely suited as Software as a Medical Device (SaMD) and is responsible for it being a rapidly expanding area of research and development. Clinical pharmacy practice may undergo major change due to the implementation of this technology. The cha